ImpactLab has acquired HeartGenetics, expanding its genetic testing capabilities and strengthening its presence in the Iberian and South American markets.
Information on the Target
HeartGenetics - Genetics and Biotechnology, S.A., based in Lisbon, Portugal, is a digital health and genetic testing company that specializes in developing actionable and cost-effective genetic tests. Founded in 2013 as a spin-off from the Instituto Superior Técnico, the company has distinguished itself in the fields of well-being, cardiovascular genetics, and pharmacogenetics. The core offering of HeartGenetics is its certified CE-IVD HEARTDECODE system, which utilizes machine learning methods for automatic reporting, demonstrating a commitment to innovative healthcare solutions.
Under the leadership of CEO and co-founder Ana Teresa Freitas, HeartGenetics has strategically positioned itself to enhance its genetic testing capabilities. With a focus on improving healthcare through genetic data and computational tools, the company has gained recognition within Portugal's growing healthcare startup ecosystem, fostering relationships and collaborations that broaden its market reach.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Portugal
Portugal's genetic testing industry is rapidly evolving, driven by advancements in biotechnology and increasing consumer awareness regarding personal health management. The demand for personalized medicine is on the rise, as more i
Similar Deals
Horizon Equity Partners → HL - Sociedade Gestora do Edifício, SA and HAÇOR - Concessionária do Edifício da Hospital da Ilha Terceira, SA
2020
Bambu Ventures → Lemonaid Health
2026
Prime Healthcare → Franciscan Health Olympia Fields
2026
ImpactLab
invested in
HeartGenetics - Genetics and Biotechnology, S.A.
in 2020
in a Buyout deal